DAWN vs. SPRY

In the year-to-date period, DAWN achieves a -49.64% return, which is significantly lower than SPRY's 36.78% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current DAWN Sharpe Ratio is -0.99, which is lower than the SPRY Sharpe Ratio of 0.91. The chart below compares the historical Sharpe Ratios of DAWN and SPRY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither DAWN nor SPRY has paid dividends to shareholders.

The maximum DAWN drawdown since its inception was -79.51%, smaller than the maximum SPRY drawdown of -95.20%. Use the drawdown chart below to compare losses from any high point for DAWN and SPRY.

Day One Biopharmaceuticals, Inc. (DAWN) and Silverback Therapeutics Inc (SPRY) have volatilities of 18.70% and 19.36%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Day One Biopharmaceuticals, Inc. and Silverback Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.